All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Nanobiotix amends J&J deal for cancer drug JNJ-1900, reducing potential milestone payments by $105M in exchange for Ph3 trial funding
Nanoparticle, head & neck cancer, radiotherapy-activated - Read more

Liquidia $100M agreement amendment with HealthCare Royalty, funding YUTREPIA development for rare cardiopulmonary diseases
Royalty, pulmonary arterial hypertension (PAH), interstitial lung disease, small molecule - Read more

PRESENTED BY DRUGBANK
Introducing the Next Evolution in Drug Discovery Intelligence

In the fast-paced world of pharmaceutical research and drug development, clarity and efficiency are everything. Yet, too often, researchers are left grappling with fragmented data sources, manual workflows, and missed opportunities.

That’s why we’re thrilled to introduce the next evolution of DrugBank.

Built on our trusted knowledge base, DrugBank consolidates fragmented drug intelligence into an intuitive AI-powered platform designed for biotech professionals to uncover insights, streamline decision-making, and accelerate drug discovery.

Be among the first to access the Future of Drug Discovery. Request Early Access Now.

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

EnteroBiotix touts positive Ph2a results for their microbiome therapy EBX-102-02 in irritable bowel syndrome with constipation
Microbiome treatment, irritable bowel syndrome (IBS), IBS with constipation - Read more

Compass Pathways' COMP360 psilocybin shows longer-lasting antidepressant effects at 25mg dose for treatment-resistant depression in Ph2 follow-up study
Small molecule, psychedelics, treatment-resistant depression - Read more

Angitia Biopharmaceuticals' showcases promising Ph1/2 results for AGA111 (recombinant human bone morphogenetic protein 6) in spinal fusion procedures, with faster fusion and improved outcomes compared to placebo
Recombinant protein, degenerative disc disease - Read more

TaiMed Biologics' TMB-365/TMB-380 (targeting CD4) dual bNAb therapy shows promising Ph2a results for HIV maintenance, offering alternative to daily oral treatment
Monoclonal antibody, human immunodeficiency virus (HIV) - Read more

Genmab's Rina-S (targeting folate receptor-alpha and TOPO1) delivers promising 55.6% response rate in Ph1/2 trial for heavily pre-treated ovarian cancer patients
Antibody-drug conjugate (ADC), ovarian cancer - Read more

THE GOOD
Company Launches

Edinburgh-based Forth Therapeutics launches with Sofinnova Partners funding to develop precision treatments targeting fibrotic diseases
Undisclosed modality, Fibrosis-driven disease - Read more

BioClec launches with Sofinnova Partners backing to develop microglia-targeting therapies for Alzheimer's disease
Undisclosed modality, Alzheimer's disease, neurodegenerative disease - Read more

Sofinnova Partners and Gustave Roussy launch Signadori Bio, a cell therapy company for cancer treatment, their first joint venture since partnering
Cell therapy, cancer, platform technology - Read more

THE GOOD
Fundraises

Sofinnova Partners €165M ($180M) Biovelocita II fund to help young drugmakers, launched three startups
Venture capital, biotech investing, life science investment - Read more

RegCell $45.8M Seed, biotech company developing Treg cell therapies for autoimmune diseases and transplantation through epigenetic reprogramming
Cell therapy, autoimmune disease, regulatory T-cell (Treg) - Read more

Arbor Biotechnologies raises $74M Series C, advancing gene editing therapy ABO-101 (targeting HAO1 gene) for rare liver condition
Gene-editing, primary hyperoxaluria type 1 - Read more

Egle Therapeutics €9.3M ($10.2M) state funding, developing Treg-targeting therapies for cancer and autoimmune diseases
Bispecific fusion protein, cancer, autoimmune disease - Read more

Optieum Biotechnologies $39M grant, developing CAR-T cell therapy targeting FAPα for glioblastoma treatment
Cell therapy, CAR-T, glioblastoma, cancer - Read more

CEL-SCI $2.5M offering, Phase 3 cancer immunotherapy company developing Multikine (interleukin) in head and neck cancer
Interleukin, squamous cell carcinoma, head & neck cancer - Read more

THE GOOD
Investments

Syngene acquires US biologics facility from Emergent BioSolutions, expanding manufacturing capacity to 50,000L for global clients
Facility sale, biologics Manufacturing, CRO (Contract Research Organization), CDMO (Contract Development & Manufacturing Organization) - Read more

THE GOOD
Lawsuits

Federal judge orders temporary reinstatement of probationary federal employees terminated during Trump administration's workforce reduction efforts.
US Department of Health & Human Services (HHS) - Read more

THE GOOD
Mergers & Acquisition

Vincerx Pharma plans to merge with AI company QumulusAI to avoid cash crisis after previous deal collapsed
Antibody-drug conjugate (ADC), AI, cancer, solid tumor - Read more

Clario acquires imaging specialist NeuroRx, expanding neuroscience capabilities after recent WCG eCOA purchase
Imaging, clinical trial-focused, CRO (Contract Research Organization) - Read more

Klick Health acquires Ward6 Singapore, expanding its Asia-Pacific presence as the largest independent healthcare marketing agency
Drug marketing, life science marketing - Read more

THE GOOD
Partnerships

Quest Diagnostics, Google Cloud collaborate in using AI for improved data management and personalized healthcare insights
AI, diagnostics - Read more

THE GOOD
Product Launches

Google launches TxGemma AI, family of models designed to empower drug discovery and help researchers “predict the safety and efficacy of potential new treatments”
Drug discovery, AI, small molecule, protein - Read more

THE GOOD
Research

Tract Bio's touts stemECHO technology for identifying therapeutic targets in esophageal cancer evolution
Epithelial stem cell cloning technology, drug discovery - Read more

Trans and nonbinary people receiving gender-affirming hormones showed significantly lower risk of depression in study of 3,500 individuals
Gender-affirming care, depression, LGBTQ+ - Read more

THE GOOD
Strategic Plans

Prime Medicine to develop gene editing treatment for rare liver/lung disorder AATD, seeking regulatory approval in 2025
Gene-editing, prime editing, alpha-1 antitrypsin deficiency - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development

Hanall Biopharma ends license with Harbour BioMed for batoclimab (targeting FcRn) due to trial delays, seeks arbitration and new partners
Monoclonal antibody, myasthenia gravis - Read more

THE BAD
Layoffs

Empress Therapeutics lays off 53% of staff (23 employees) as the biotech focuses on advancing small-molecule science to clinic
Small molecule, drug discovery, AI, synthetic biology - Read more

Pyxis cuts 20% of staff, including CMO, to focus on single cancer antibody-drug conjugate after pipeline trimming
Antibody-drug conjugate (ADC), lung cancer - Read more

Cash-strapped Kiromic BioPharma furloughs 31 employees, halting research until financing secured to resume operations
Cell therapy, lung cancer, allogeneic cell therapy, non-viral delivery, gamma-delta T cell therapy - Read more

TC BioPharm cuts 50% of workforce, outsources manufacturing to reduce burn rate by 55% and save $4.2M annually
Cell therapy, allogeneic cell therapy, gamma-delta T cell therapy, myeloid leukemia - Read more

Novartis laying off 427 New Jersey employees as heart medication Entresto's patent expires (following 235 layoffs last year)
Big pharma layoffs, small molecule, heart failure - Read more

Stem cell company bit.bio cuts 25% of staff, shifts focus from therapeutics to selling engineered cell lines
Stem cell-derived therapy, induced pluripotent stem cell (IPSC/iPS cell), regulatory T-cell (Treg), cell line - Read more [Paywall]

THE BAD
Politics & Policy

CDC federal workers fired under Trump still not contacted by HHS for reinstatement, despite court order requiring notification and reinstatement
Centers for Disease Control and Prevention (CDC) - Read more

THE UGLY
Adverse Events

Patient dies from acute liver failure after taking Sarepta's Duchenne muscular dystrophy gene therapy Elevidys (targeting dystrophin gene); company's stock plunges 22%
Gene therapy, Duchenne muscular dystrophy (DMD) - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here